Drugs / E3810
E3810
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01153659 | Jul → Aug 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT01397448 | Jul 2011 → Mar 2013 | active peptic ulcer disease | Eisai Inc. | Completed | Met primary |
| Phase 2/3 | NCT00770913 | Oct 2008 → Nov 2009 | peptic esophagitis | Eisai Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00165646 | Sep 2004 → Oct 2005 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
Press releases naming this drug 18 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E3810 | “Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)” NCT01397448 ↗ |
| Known as | Pariet | “To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal...” NCT00165646 ↗ |
| Known as | Rabeprazole | “Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)” NCT01397448 ↗ |
| Known as | Rabeprazole Sodium | “To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal...” NCT00165646 ↗ |
| Route | Oral | “E3810 5mg: once daily orally for 4 weeks” NCT00165646 ↗ |